Home

Founded on a biology-first approach, the company has developed proprietary AI and experimental platforms that drive deep mechanistic understanding of disease across the full drug development cycle, advancing programmes in bone, cardiorenal, dermatology and rheumatology.

Focus on diseases where we transform confidence in biology 
 • Using AI, genetics and massive proprietary datasets.

Determine what biology to prosecute for a given disease
 • Using the Relation Discovery Platform.

Discover or acquire molecules, working with leading partners
 • Remain modality agnostic, let the biology speak.

Deploy AI and data to improve clinical probability of success
 • Using the Relation Development Platform.

Develop molecules to clinical value inflection points
 • Asset centric development with deep translational thought.